NASDAQ:EYPT EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $9.71 +0.25 (+2.64%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.44▼$9.9150-Day Range$8.01▼$12.1452-Week Range$5.67▼$30.99Volume377,778 shsAverage Volume892,930 shsMarket Capitalization$505.70 millionP/E RatioN/ADividend YieldN/APrice Target$33.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get EyePoint Pharmaceuticals alerts: Email Address EyePoint Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside242.8% Upside$33.29 Price TargetShort InterestBearish19.35% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.95Based on 3 Articles This WeekInsider TradingAcquiring Shares$10.08 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.21) to ($2.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.00 out of 5 starsMedical Sector412th out of 936 stocksAnalytical Instruments Industry13th out of 27 stocks 4.5 Analyst's Opinion Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyePoint Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about EyePoint Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.35% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently increased by 4.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEyePoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyePoint Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYPT. Previous Next 2.8 News and Social Media Coverage News SentimentEyePoint Pharmaceuticals has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for EyePoint Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows6 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EyePoint Pharmaceuticals insiders have bought 3,718.50% more of their company's stock than they have sold. Specifically, they have bought $10,081,000.00 in company stock and sold $264,004.00 in company stock.Percentage Held by InsidersOnly 4.74% of the stock of EyePoint Pharmaceuticals is held by insiders.Percentage Held by Institutions99.41% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about EyePoint Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($2.21) to ($2.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EyePoint Pharmaceuticals is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EyePoint Pharmaceuticals is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyePoint Pharmaceuticals has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about EyePoint Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Read More EYPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYPT Stock News HeadlinesJuly 17, 2024 | insidertrades.comInsider Selling: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Director Sells 11,625 Shares of StockJuly 21, 2024 | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by BrokeragesJuly 27, 2024 | True Market Insiders (Ad)The #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…July 18, 2024 | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Sees Large Increase in Short InterestJuly 17, 2024 | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Director David R. Guyer Sells 11,625 Shares of StockJuly 16, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 18, 2024 | globenewswire.comEyePoint Pharmaceuticals to Host R&D Day on June 26, 2024June 17, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 27, 2024 | True Market Insiders (Ad)The #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…June 5, 2024 | globenewswire.comEyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | finance.yahoo.comInvesting in EyePoint Pharmaceuticals (NASDAQ:EYPT) a year ago would have delivered you a 91% gainMay 17, 2024 | finance.yahoo.comInsider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)May 16, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 13, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals: Maintaining Buy Rating Amidst Progress and TrialsMay 10, 2024 | finance.yahoo.comEyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite ChallengesMay 8, 2024 | investorplace.comEYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsMay 7, 2024 | markets.businessinsider.comMaintaining Buy Rating on EyePoint Pharmaceuticals Despite P2 Study SetbackSee More Headlines Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/27/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:EYPT CUSIPN/A CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees120Year Founded1987Price Target and Rating Average Stock Price Target$33.29 High Stock Price Target$44.00 Low Stock Price Target$28.00 Potential Upside/Downside+242.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,790,000.00 Net Margins-157.77% Pretax Margin-157.60% Return on Equity-49.94% Return on Assets-30.94% Debt Debt-to-Equity RatioN/A Current Ratio5.08 Quick Ratio5.01 Sales & Book Value Annual Sales$46.02 million Price / Sales10.99 Cash FlowN/A Price / Cash FlowN/A Book Value$5.66 per share Price / Book1.72Miscellaneous Outstanding Shares52,080,000Free Float49,615,000Market Cap$505.70 million OptionableOptionable Beta1.58 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Jay S. Duker M.D. (Age 65)President, CEO & Director Comp: $848.5kDr. John B. Landis M.S. (Age 71)Ph.D., Interim Head of R&D and Director Comp: $63.75kMr. Michael Pine (Age 47)Chief Business Officer Comp: $764.85kMr. George O. Elston (Age 59)Executive VP & CFO Comp: $743.86kMr. Michael J. MaciocioSenior Vice President of Manufacturing & OperationsMr. Ron I. Honig Esq.Chief Legal Officer & Company SecretaryMs. Jennifer LeonardChief People Officer & Senior VP of ITMr. David Scott Jones (Age 56)Senior VP & Chief Commercial Officer Comp: $672.08kMs. Isabelle LefebvreChief Regulatory OfficerDr. Marcia Sellos-Moura Ph.D.Senior Vice President of Program LeadershipMore ExecutivesKey CompetitorsFluidigmNASDAQ:FLDMTranscatNASDAQ:TRNSCytek BiosciencesNASDAQ:CTKBStandard BioToolsNASDAQ:LABQuanterixNASDAQ:QTRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 50,388 shares on 7/26/2024Ownership: 0.393%Legato Capital Management LLCSold 52,297 shares on 7/26/2024Ownership: 0.037%SG Americas Securities LLCBought 76,288 shares on 7/12/2024Ownership: 0.146%David R GuyerSold 11,625 sharesTotal: $116,947.50 ($10.06/share)Woodstock CorpBought 24,609 shares on 7/8/2024Ownership: 0.106%View All Insider TransactionsView All Institutional Transactions EYPT Stock Analysis - Frequently Asked Questions How have EYPT shares performed this year? EyePoint Pharmaceuticals' stock was trading at $23.11 at the start of the year. Since then, EYPT shares have decreased by 58.0% and is now trading at $9.71. View the best growth stocks for 2024 here. How were EyePoint Pharmaceuticals' earnings last quarter? EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.21. The firm earned $11.68 million during the quarter, compared to analysts' expectations of $12.50 million. EyePoint Pharmaceuticals had a negative net margin of 157.77% and a negative trailing twelve-month return on equity of 49.94%. When did EyePoint Pharmaceuticals' stock split? Shares of EyePoint Pharmaceuticals reverse split on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are EyePoint Pharmaceuticals' major shareholders? Top institutional shareholders of EyePoint Pharmaceuticals include Bank of New York Mellon Corp (0.39%), SG Americas Securities LLC (0.15%), Woodstock Corp (0.11%) and Legato Capital Management LLC (0.04%). Insiders that own company stock include Ew Healthcare Partners, LP, Ye Liu, David Scott Jones, Dario A Paggiarino, Michael Craig Pine and David R Guyer. View institutional ownership trends. How do I buy shares of EyePoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of EyePoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX) and Catalyst Pharmaceuticals (CPRX). This page (NASDAQ:EYPT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
